Table 3 Responses to the treatment
Response rates | Total | CR (%) | CRi (%) | PR (%) | TF (%) | ORR (%) |
|---|---|---|---|---|---|---|
Dose | ||||||
 60 mg | 3 (15%) | 1 (33%) | 0 | 0 | 2 (66%) | 1 (33%) |
 80 mg | 17 (85%) | 9 (53%) | 3 (18%) | 1 (6%) | 4 (24%) | 13 (76%) |
Age | ||||||
 Age ≤ 60a | 10 (50%) | 6 (60%) | 1 (10%) | 1 (10%) | 2 (20%) | 8 (80%) |
 Age > 60b | 10 (50%) | 4 (40%) | 2 (20%) | 0 | 4 (40%) | 6 (60%) |
AML diagnosis | ||||||
 Newly diagnosed | 12 (60%) | 7 (58%) | 3 (25%) | 1 (8%) | 1 (8%) | 11 (92%) |
 Relapsed/refractory | 8 (40%) | 3 (38%) | 0 | 0 | 5 (63%) | 3 (38%) |
European LeukemiaNet risk group | ||||||
 Favorable | 3 (15%) | 3 (100%) | 0 | 0 | 0 | 3 (100%) |
 Intermediate I/II | 9 (45%) | 4 (44%) | 2 (22%) | 0 | 3 (33%) | 6 (67%) |
 Adverse | 8 (40%) | 3 (38%) | 1 (13%) | 1 (13%) | 3 (38%) | 5 (63%) |
Total | 20 (100%) | 10 (50%) | 3 (15%) | 1 (5%) | 6 (30%) | 14 (70%) |